Different tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice Source: Eur Respir J 2006; 28: Suppl. 50, 433s Year: 2006
Tissue retention and esterification is greater for budesonide than for ciclesonide in trachea ex vivo Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
The uptake of ciclesonide-active metabolite and budesonide into human hepatocytes in vitro – the effect of serum protein binding Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
Unbound pharmacologically active metabolite des-CIC is not detectable in human skeletal muscle and subcutaneous adipose tissue after inhalation of high-dose ciclesonide Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
Pronounced tissue and plasma protein binding of ciclesonide is responsible for reduced pharmacodynamic potency in the lung Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007
Exposure of human subcutaneous adipose tissue and skeletal muscle tissue to unbound active drug after inhalation of high-dose ciclesonide or budesonide Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007
Greater esterification and retention of budesonide in the airways and lung as compared to ciclesonide after repeated intratracheal administration in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
Deposition and metabolism of inhaled ciclesonide in the human lung Source: Eur Respir J 2010; 36: 1113-1119 Year: 2010
Determination of tissue concentrations of metabolites in surgical preparations following inhalation of beclomethasone-dipropionate using conventional and extrafine aerosols Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003
The combination of budesonide and formoterol exerts more rapid and enhanced anti-inflammatory effects than either drug alone in rat lungs in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004
Esterification prolongs retention of budesonide but not ciclesonide - active principle in rat trachea Source: Eur Respir J 2005; 26: Suppl. 49, 369s Year: 2005
Uptake, retention and metabolism of ciclesonide in human alveolar epithelial cells Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005
Efficient deposition and absorption of orally inhaled indacaterol in the lungs Source: Annual Congress 2011 - COPD management Year: 2011
Highly lipophilic fatty acid esters of the active metabolite of ciclesonide formed in vitro in rat lung tissue Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
Proteoglycan production in cultured human lung fibroblasts is synergistcally inhibited by combination of budesonide and formoterol Source: Eur Respir J 2003; 22: Suppl. 45, 286s Year: 2003
TGFβ-induced proteoglycan production and α-smooth muscle actin expression in cultured human lung fibroblasts is inhibited by combination of budesonide and formoterol Source: Eur Respir J 2004; 24: Suppl. 48, 251s Year: 2004
Glycosaminoglycan synthesis is modulated by ciclesonide in human lung cells Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004
Single and combined effects of budesonide and formoterol on oxygen dependent metabolism of blood cells Source: Annual Congress 2010 - Novel insights into the pathophysiology of asthma and COPD Year: 2010
Pulmonary targeting of ciclesonide and its active metabolite as determined in an ex-vivo rat receptor-binding assay Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002
LATE-BREAKING ABSTRACT: Roflumilast and its active metabolite inhibit LPS-induced cytokines production from human parenchymal and bronchial explants: interaction with formoterol Source: Annual Congress 2009 - Airway cell biology Year: 2009